Diarylsulfonylureas--a new class of antitumor agents
1Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Box 2202C, Brookings, SD 57007-0099, USA. GUANX@MG.sdstate.edu
Abstract:
Diarylsulfonylureas (DSU) represent a new class of antitumor agents. DSU exhibit an exceptionally broad spectrum of activity against solid tumors. They show different toxicity to conventional anticancer agents and exhibit no cross-resistance with existing anticancer agents. In particular they have an unknown, but unique, potentially novel mechanism of action. Sulofenur is the first DSU to progress to clinical evaluation. The dose-limiting toxicity in humans is anemia and methemoglobinemia. Recently, DSU with novel structural features have also been reported to exhibit potent antitumor activity, demonstrating structural diversity of DSU antitumor agents.
Related Concept Videos
Oral Hypoglycemic Agents: Sulfonylureas
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: Biguanides and Glitazones
Antihypertensive Drugs: Thiazide-Class Diuretics
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors

